HomeAI · summaries
Storia in 2 fonti
HSE decision on Friederich’s ataxia welcome, but highlights ever-present conundrum
Amid demand for best-in-class drugs, the State’s medicine bill is approaching €4bn annually
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
irishtimes.com
Friedreich’s ataxia: ‘We haven’t got time. We just simply need a chance’
Patients and families are calling on the HSE to fund Skyclarys, a treatment they say could help slow progression of the rare disease
- ·
Decision due on HSE funding for treatment for rare genetic disorder
The drug omaveloxolone, branded as Skyclarys, was approved in the US for the treatment of the disease, followed by Europe
